Related Experiment Video

Updated: Jul 3, 2026

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse
04:14

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse

Published on: October 6, 2023

Case report: thyroid hormone resistance and its therapeutic challenges

Toni J Kim1, Sharon Travers

  • 1Department of Pediatrics, Division of Pediatric Endocrinology, The Children's Hospital, Denver, Colorado, USA. Toni.kim@uchsc.edu

Current Opinion in Pediatrics
|July 16, 2008
PubMed

Insights

Thyroid hormone resistance, caused by genetic mutations, presents challenges in treatment. This case study optimizes growth and development in a young patient with this rare condition.

Area of Science:

  • Endocrinology
  • Genetics
  • Molecular Biology

Background:

  • Thyroid hormone resistance (THR) arises from genetic mutations in the thyroid hormone receptor, impairing hormone binding.
  • This leads to reduced receptor affinity and altered circulating free thyroid hormone levels.
  • THR is linked to diverse phenotypes, including developmental and behavioral issues, complicating management.

Observation:

  • A pediatric patient presented with early-onset thyroid hormone resistance.
  • Common symptoms observed included hyperactivity, emotional lability, below-average IQ, and short stature.
  • The patient's presentation offered a unique opportunity for early intervention to optimize growth and development.

Findings:

  • The study details the clinical presentation of a child with early-onset thyroid hormone resistance.
  • It highlights the challenges in managing this condition, particularly in pediatric populations.
  • The report reviews existing literature on treating thyroid hormone resistance in children.

Implications:

  • Early diagnosis and intervention are crucial for managing thyroid hormone resistance in children.
  • Optimizing treatment strategies can improve overall growth and neurodevelopmental outcomes.
  • Further research is needed to establish standardized treatment protocols for pediatric THR.

Related Concept Videos

Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...